Results 21 to 30 of about 781,343 (307)

Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial

Arthritis & Rheumatology, 2022
To analyze the efficacy and safety of nintedanib in patients with fibrosing autoimmune disease–related interstitial lung diseases (ILDs) with a progressive phenotype.
E. Matteson, C. Kelly, J. Distler, A. Hoffmann-Vold, J. Seibold, S. Mittoo, P. Dellaripa, M. Aringer, J. Pope, O. Distler, A. James, R. Schlenker‐Herceg, S. Stowasser, M. Quaresma, K. Flaherty   +14 more
semanticscholar   +1 more source

Immunomodulatory treatment of interstitial lung disease

Therapeutic Advances in Respiratory Disease, 2022
Interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) have an array of immunomodulatory treatment options compared with IPF, due to their inflammatory component.
L. van den Bosch, F. Luppi, G. Ferrara, M. Mura   +3 more
semanticscholar   +1 more source

In-hospital mortality following surgical lung biopsy for interstitial lung disease in the USA: 2000-2011 [PDF]

, 2016
Rationale: Surgical lung biopsy can help to determine a specific diagnosis in interstitial lung disease, but has associated risks. Most currently available mortality data are derived from case series and may not be generalizable to broader populations.
Fogarty, Andrew W., Hubbard, Richard B., Hutchinson, John P., McKeever, Tricia M.   +3 more
core   +1 more source

Interstitial lung disease: course report [PDF]

Breathe, 2020
The @EuroRespSoc course on ILD https://bit.ly/32PtzfH.
Michael Kreuter, Vitalii Poberezhets
openaire   +2 more sources

Palliative care for people with non-malignant lung disease: summary of current evidence and future direction [PDF]

, 2013
Background: The physical and psychosocial needs of patients with chronic non-malignant lung disease are comparable to those with lung cancer. This article will focus on chronic obstructive pulmonary disease, interstitial lung disease and cystic fibrosis ...
Boland, Jason, Martin, Jonathan, Ross, Joy R, Ross, Joy R., Wells, Athol U, Wells, Athol U.   +5 more
core   +1 more source

Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open Label Extension of a Phase 3 Randomized Controlled Trial.

American Journal of Respiratory and Critical Care Medicine, 2021
RATIONALE Tocilizumab, an anti-interleukin-6 receptor antibody, had no statistically significant effect on skin sclerosis but preserved lung function over 48 weeks in patients with early systemic sclerosis-associated interstitial lung disease in a phase ...
D. Khanna, Celia J. F. Lin, D. Furst, Bridget Wagner, M. Zucchetto, G. Raghu, F. Martinez, J. Goldin, J. Siegel, C. Denton   +9 more
semanticscholar   +1 more source

Interstitial lung disease [PDF]

European Respiratory Review, 2013
This article reviews the most important articles published in interstitial lung disease, as reviewed during the Clinical Year in Review session at the 2012 annual European Respiratory Society Congress in Vienna, Austria.Since the recent international guidelines for the management of idiopathic pulmonary fibrosis (IPF), important new evidence is ...
openaire   +4 more sources

Interstitial lung disease in Primary Sjögren's syndrome

BMC Pulmonary Medicine, 2022
Background Interstitial lung disease (ILD) may cause life-threatening complications of primary Sjogren’s syndrome (pSS), and has a poor prognosis in terms of survival and quality of life.
wei lin, Zhifei Xin, Jianlong Zhang, Ning Liu, X. Ren, Meilu Liu, Ya-latu Su, Yixuan Liu, Liu Yang, Shaoying Guo, Yupeng Yang, Yang Li, Jingjing Cao, Xiaoran Ning, Jingjing Li, He Xue, N. Niu, Ying-qun Chen, Fang Li, Lijun Sun, Xiaopeng Zhang, Fengxiao Zhang, Wen Zhang   +22 more
semanticscholar   +1 more source

Comorbidities in interstitial lung diseases

European Respiratory Review, 2017
Fibrosing lung disorders include a large number of diseases with diverse behaviour. Patients can die because of the progression of their illness, remain stable or even improve after appropriate treatment has been instituted.
George A. Margaritopoulos, Katerina M. Antoniou, Athol U. Wells   +2 more
doaj   +1 more source

Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry

European Respiratory Journal, 2021
Pulmonary hypertension (PH) is a common complication of many chronic lung diseases, especially COPD and interstitial lung disease (ILD) [1]. In these conditions, the development of PH is associated with an aggravation of symptoms and an increase in ...
K. Olsson, M. Hoeper, C. Pausch, E. Grünig, D. Huscher, D. Pittrow, S. Rosenkranz, H. Gall   +7 more
semanticscholar   +1 more source